STAT+: Bernie Sanders may have reached the limits of his pharma pressure campaign
WASHINGTON — Bernie Sanders is figuring out just how far bullying drugmakers can take him….
Category: drug prices
AstraZeneca antibody reduced Covid-19 risk in immunocompromised
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Blackstone wants in on red-hot immunology market
The need-to-know this morning Biogen and Ionis Pharmaceuticals are ending their development of an experimental drug for ALS based on…
Leqembi gets closer to being offered as an injection
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Is Novavax a new meme stock?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
We now know Tome’s gene editing target
Want to stay on top of the science and politics driving biotech today? Sign up to get…
The public wants Medicare to cover obesity drugs
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Yet another big financing round in immunology
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Pharma has over $500B in capital for deals
Want to stay on top of the science and politics driving biotech today? Sign up to get…
.jpg)
Vertex starts gene therapy Casgevy in five patients
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Merck may have a competition for ever-scarce BCG
Want to stay on top of the science and politics driving biotech today? Sign up to get…
ICER casts doubt on Sarepta’s DMD gene therapy
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Novo Nordisk defends Ozempic price in face of Senate scrutiny
Novo Nordisk defended the prices of its blockbuster diabetes and obesity drugs Ozempic and Wegovy…
The biotech news you need to read this morning
Want to stay on top of the science and politics driving biotech today? Sign up to get…
The latest government crackdowns on biotech you need to know
Want to stay on top of the science and politics driving biotech today? Sign up to get…
FDA wants to hear your thoughts on advisory committees
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Bernie Sanders targets ‘outrageously high price’ of Ozempic
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Biosimilars haven’t always yielded lower out-of-pocket costs for patients, study finds
Two years after biosimilars became available in the U.S., a higher proportion of patients using…
Biohaven’s data delay degrades stock price
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Chuck Schumer’s broken promise on affordable insulin
WASHINGTON — In February 2022, Senate Majority Leader Chuck Schumer stood alongside constituents in Buffalo,…
A two-decade bet on Seagen pays off
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Colorado lawmakers revise effort to exempt rare disease drugs from state cost caps
In response to controversy, a group of Colorado lawmakers is abandoning a bill that would…
What about the company Vertex didn’t buy?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharmalittle: We’re reading about AstraZeneca CEO pay, alternatives to WuXi and more
And so, another working week will soon draw to a close. Not a moment too…
Gas prices are hurting biotech
Want to stay on top of the science and politics driving biotech today? Sign up to get…
AskBio CSO steps down, has new project in stealth mode
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Did you say 486%? Why one company thinks such a price hike for its drug is justified
In an era when huge price hikes for prescription drugs are almost guaranteed to draw…
STAT+: Virginia governor vetoes plans to create a prescription drug affordability board
Virginia Gov. Glenn Youngkin vetoed a bill that would have created a new entity for…
STAT+: Biden administration urged to license prostate cancer drug patents in a bid to lower its cost
In the latest gambit to lower the cost of a pricey medicine, three advocacy groups…
Pfizer’s plot to win the RSV vaccine race
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Sanofi resolves most Zantac litigation
Want to stay on top of the science and politics driving biotech today? Sign up to get…
How resurrecting extinct species might impact medicine
Want to stay on top of the science and politics driving biotech today? Sign up to get…
New data on liquid biopsy for colorectal cancer detection still underwhelms
Want to stay on top of the science and politics driving biotech today? Sign up to get…
Opinion: Medicare coverage of weight loss drugs could save the U.S. billions of dollars
The latest weight loss drugs are good. Really good. They can save lives and could…
STAT+: The White House has a plan to stem drug shortages
WASHINGTON — The White House at long last published a plan to stem drug shortages,…
Lawmakers want to add more Chinese biotechs to defense list
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Watch: Medicare billing forms are running out of space for growing health care prices
WASHINGTON — Health care costs are getting so high that prices are literally running off…
Aardvark Therapeutics gearing up for $200 million IPO
Want to stay on top of the science and politics driving biotech today? Sign up to get…
GLP-1 generics would be dramatically cheaper than U.S. price of Ozempic, study shows, but still profitable
Diabetes drugs are too expensive in the U.S., and insulin is infamously six to 13…
What’s Congress going to do with WuXi?
Want to stay on top of the science and politics driving biotech today? Sign up to get…
How GLP-1’s moved from research labs to national TV
Today is the inaugural publishing day for Adam’s Biotech Scorecard — a subscriber-only newsletter offering…
Brazil’s plan for low-cost CAR-Ts
New biotech newsletter launching tomorrow. Don’t miss out. Good morning, everyone. Damian here with the…
Merck’s next big thing is (probably) on the way
New biotech newsletter launching this Thursday. Don’t miss out. Hello, everyone. Damian here with a look…
STAT+: Amgen sues Colorado over its prescription drug affordability board
Amgen has filed a lawsuit accusing a Colorado state board of violating the U.S. Constitution…
How will the Supreme Court’s mifepristone decision impact biopharma?
New biotech newsletter launching this Thursday. Don’t miss out. Hey there. Today, we discuss the…
STAT+: How biotech investors spot opportunity when stocks are down — and up
Following a blockbuster year of dealmaking and a recent uptick in biotech stocks, top investors…
STAT+: Despite new Wegovy coverage, Medicare patients may face high drug costs and other hurdles
Medicare confirmed this week that it will cover Novo Nordisk’s obesity drug Wegovy if prescribed…
EU adviser says Illumina merger was not problematic
Want to stay on top of the science and politics driving biotech today? Sign up to get…
BioNTech is having its Pfizer moment
Want to stay on top of the science and politics driving biotech today? Sign up to get…
STAT+: Pharma companies and their allies seek to exempt orphan drugs from state pricing limits
As more states create dedicated boards to cap the costs of medicines, some drugmakers and…